Longitudinal RNA-seq profiling of purified Treg and Teff cells in patients with autoimmune and autoinflammatory diseases treated with low-dose IL-2
This study reports longitudinal RNA-seq profiling of purified regulatory T cells (Tregs) and effector T cells (Teffs) from patients with autoimmune and autoinflammatory diseases treated with low-dose IL-2 in the TRANSREG clinical trial. Peripheral blood samples were collected at baseline, day 8, and month 3 after treatment initiation. The dataset was generated to characterize treatment-induced transcriptomic changes in T cell subsets and to identify molecular signatures associated with clinical response, with a particular focus on interferon-stimulated genes and IL-2-related regulatory pathways.